Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18763347 | 0.90 | MT-CO2 (0.41) | GAAHTTALDH1A1RAB9ANR1D1 | |
| SCHEMBL18740589 | 0.87 | AKT1 (0.38) | CYP2C19PPARAPPARGAKT1SMN1; SMN2 | |
| SCHEMBL18740536 | 0.85 | RIPK1 (0.44) | ALDH1A1NR1D1LMNAAKT1MAPT | |
| SCHEMBL19448804 | 0.78 | L3MBTL1 (0.48) | HTTAKT1MEN1KMT2A | |
| SCHEMBL18763338 | 0.77 | HDAC6 (0.40) | CYP2C19PPARAPPARGAKT1SMN1; SMN2 | |
| SCHEMBL5716073 | 0.75 | HDAC6 (0.39) | RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18763349 | 0.75 | RIPK1 (0.43) | NR1D1 | |
| SCHEMBL15659860 | 0.74 | L3MBTL1 (0.47) | HTTALDH1A1NR1D1SMN1; SMN2NPSR1 | |
| SCHEMBL30264860 | 0.74 | ALDH1A1 (0.57) | GAAHTTALDH1A1RAB9ANR1D1 | |
| SCHEMBL16971619 | 0.74 | ALDH1A1 (0.45) | GAAHTTALDH1A1RAB9ANR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954225-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3362447-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200115370-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180312495-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3362447-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066368-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115370-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN1 | GAA 1631/4885HTT 887/4885ALDH1A1 1839/4885 |
| US-10954225-B2 | Selective NR2B antagonists | GRIN2B, GRIN2A, GRIN1 | GAA 1631/4885HTT 887/4885ALDH1A1 1839/4885 |
| US-20180312495-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2A, GRIN2B, GRIN1 | GAA 1382/4885HTT 463/4885ALDH1A1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.